Inactivation of Bacillus subtilis glutamine synthetase by metal-catalyzed oxidation.
Instability of Bacillus subtilis glutamine synthetase in crude extracts was attributed to site-specific oxidation by a mixed-function oxidation, and not to limited proteolysis by intracellular serine proteases (ISP). The crude extract from B. subtilis KN2, which is deficient in three intracellular proteases, inactivated glutamine synthetase similarly to the wild-type strain extract. To understand the structural basis of the functional change, oxidative modification of B. subtilis glutamine synthetase was studied utilizing a model system consisting of ascorbate, oxygen, and iron salts. The inactivation reaction appeared to be first order with respect to the concentration of unmodified enzyme. The loss of catalytic activity was proportional to the weakening of subunit interactions. B. subtilis glutamine synthetase was protected from oxidative modification by either 5 mM Mn2+ or 5 mM Mn2+ plus 5 mM ATP, but not by Mg2+. The CD-spectra and electron microscopic data showed that oxidative modification induced relatively subtle changes in the dodecameric enzyme molecules, but did not denature the protein. These limited changes are consistent with a site-specific free radical mechanism occurring at the metal binding site of the enzyme. Analytical data of the inactivated enzyme showed that loss of catalytic activity occurred faster than the appearance of carbonyl groups in amino acid side chains of the protein. In B. subtilis glutamine synthetase, the catalytic activity was highly sensitive to minute deviations of conformation in the dodecameric molecules and these subtle changes in the molecules could be regarded as markers for susceptibility to proteolysis.
Kimura
K
K
Laboratory of Biochemistry, College of Science, Rikkyo (St. Paul's) University, Tokyo.
Sugano
S
S
D001412:Bacillus subtilis / Q000201:enzymology* / Q000235:genetics; D002474:Cell-Free System; D002942:Circular Dichroism; D004492:Edetic Acid / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D004795:Enzyme Stability; D004926:Escherichia coli / Q000235:genetics; D005798:Genes, Bacterial; D005974:Glutamate-Ammonia Ligase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000648:ultrastructure; D007700:Kinetics; D008274:Magnesium / Q000494:pharmacology; D008345:Manganese / Q000494:pharmacology; D008670:Metals / Q000494:pharmacology*; D008854:Microscopy, Electron; D008970:Molecular Weight; D010084:Oxidation-Reduction; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000648:ultrastructure; D013439:Sulfhydryl Reagents / Q000494:pharmacology
D008670:Metals; D011994:Recombinant Proteins; D013439:Sulfhydryl Reagents; D008345:Manganese; D004533:Egtazic Acid; D004492:Edetic Acid; D005974:Glutamate-Ammonia Ligase; D008274:Magnesium